How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX shares have decreased by 66.8% and is now trading at $3.12. View the best growth stocks for 2023 here .

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 11,200 shares, a decrease of 36.0% from the October 31st total of 17,500 shares. Based on an average daily volume of 15,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.2% of the company's shares are short sold. View Akari Therapeutics' Short Interest .

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , Biocept (BIOC) , OPKO Health (OPK) , Anavex Life Sciences (AVXL) , Rigel Pharmaceuticals (RIGL) , Teva Pharmaceutical Industries (TEVA) , Vascular Biogenics (VBLT) and Heat Biologics (HTBX) .

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%). View institutional ownership trends .

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX)

$3.12

-0.03 (-0.95%)

(As of 12/8/2023 ET)

Compare

Today's Range: $3.06
▼
$3.26
50-Day Range: $2.91
▼
$3.88
52-Week Range: $2.81
▼
$11.43

Volume: 6,794 shs
Average Volume: 8,595 shs
Market Capitalization: $17.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Ownership SEC Filings Short Interest Social Media

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKTX Stock News Headlines

December 2, 2023 | investing.com

Akari Therapeutics (AKTX) Earnings Dates & Reports

December 2, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 1, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday Trading

December 1, 2023 | americanbankingnews.com

Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Declines By 36.0%

November 28, 2023 | sg.finance.yahoo.com

Akari Therapeutics, Plc (CLA.F)

November 24, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Climb Higher Friday

November 16, 2023 | finance.yahoo.com

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

December 9, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 14, 2023 | msn.com

Travel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday

November 6, 2023 | finance.yahoo.com

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

October 3, 2023 | finance.yahoo.com

Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

September 29, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

September 29, 2023 | finance.yahoo.com

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

September 27, 2023 | finance.yahoo.com

Akari Therapeutics to Present at Emerging Growth Conference

September 21, 2023 | finance.yahoo.com

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

September 19, 2023 | finance.yahoo.com

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

September 5, 2023 | finance.yahoo.com

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 31, 2023 | msn.com

Akari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10

August 21, 2023 | finance.yahoo.com

British pharma opens U.S. headquarters in Boston

August 18, 2023 | finance.yahoo.com

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

August 17, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces ADS Ratio Change

August 15, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics, Plc Announces ADS Ratio Change

August 15, 2023 | msn.com

Akari Therapeutics announces ADS ratio change

August 15, 2023 | finance.yahoo.com

Akari Therapeutics, Plc Announces ADS Ratio Change

August 2, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

August 2, 2023 | finance.yahoo.com

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

See More Headlines

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/31/2020
Today: 12/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.56
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 6.50

Miscellaneous

Outstanding Shares: 5,650,000
Free Float: 2,159,000
Market Cap: $17.63 million
Optionable: Not Optionable
Beta: 1.13

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Ms. Rachelle Suzanne Jacques (Age 52)
President, CEO & Director
Comp: $1.38M
Ms. Wendy F. DiCicco CPA (Age 56)
Interim Chief Financial Officer
Ms. Melissa Bradford-Klug (Age 53)
Chief Operating Officer
Dr. Miles Nunn (Age 54)
Chief Scientific Officer
Dr. John F. Neylan III (Age 70)
M.D., Executive VP & Chief Medical Officer
Ms. Beth-Anne Lang
Senior Vice President of Regulatory Affairs
Annie Mack
Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

Sabby Management LLC
Sold 7,214,040 shares on 11/15/2023
Ownership: 3.152%

View All Institutional Transactions

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed in 2023?: Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX shares have decreased by 66.8% and is now trading at $3.12.
View the best growth stocks for 2023 here.
Are investors shorting Akari Therapeutics?: Akari Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 11,200 shares, a decrease of 36.0% from the October 31st total of 17,500 shares. Based on an average daily volume of 15,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.2% of the company's shares are short sold.
View Akari Therapeutics' Short Interest.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.
When did Akari Therapeutics' stock split?: Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).
Who are Akari Therapeutics' major shareholders?: Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%).
View institutional ownership trends.
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial